SMMT Summit Therapeutics RESULTS: Q2, Q2 EPS $-0.28, Q2 Net Income $-215.7M, Q2 operating expenses $220.5M

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.